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Background
The growing list of associations between idiosyncratic
adverse drug reactions and variants of the Human Leuko-
cyte Antigen (HLA) molecule is suggestive of specific
interactions between the causative drug and the associated
HLA molecule. Currently, most of our understanding of
how HLA molecules stimulate drug specific T cell
responses comes from observing the conditions necessary
for T cell stimulation (e.g. specific HLA, time for drug
metabolism, constant drug presence, antigen processing).
Whilst this provides indirect evidence of the presence of
immunogenic ligands on the cell surface it does not deter-
mine the precise nature of the immunogenic HLA ligand
(s). Using a mixture of mass spectrometry (MS) and struc-
tural biology techniques we recently defined the mode of
interaction between abacavir and HLA-B*57:01. We
showed how, by occupying the antigen binding cleft, aba-
cavir changes the array of peptides bound by the HLA
molecule, furnishing circulating T cells with numerous
novel, potentially immunogenic, HLA-B*57:01-abacavir-
peptide complexes. Regardless, there is still some debate
as to whether T cell responses to abacavir are elicited by i)
the binding of abacavir to HLA-peptide complexes directly
at the cell surface to generate immediately available immu-
nogenic complexes, ii) the loading of novel, abacavir
enabled ligands in the endoplasmic reticulum, or iii) a
mixture of both.
Methods and results
Here we use targeted MS experiments to simultaneously
monitor the binding of abacavir to, and changes in peptide
presentation by, HLA-B*57:01+ cells over time, tracking a
series of peptides known to bind HLA-B*57:01 under dif-
ferent conditions. We show that abacavir binding and
changes in peptide presentation mirror the time course for
maximal antigenicity of abacavir-treated HLA-B*57:01+
cell lines for abacavir responsive T cell lines, suggesting
that the major part of the response is towards the binding
of novel peptides.
Conclusions
The MS techniques used here successfully tracked drug
induced changes in antigen presentation by the HLA
molecule and may be adapted to monitor drug induced
changes in antigen presentation in other HLA-associated
drug hypersensitivities.
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